ADORA2B and atherosclerosis: Immunohistochemistry in the non-atherosclerosis cohort was performed, demonstrating a 44.6% (p = 0.045) relative reduction in SMC content in the NI of rabbits treated with dipyridamole over controls with peri-strut localization of ADOR-A2B noted (Figure 3).